| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/16/2003 | WO2002002772A3 Human extracellular matrix (ecm)-related tumor marker |
| 01/16/2003 | WO2001095874A3 Highly efficient delivery of a large therapeutic mass aerosol |
| 01/16/2003 | WO2001093913A3 T cell receptor fusions and conjugates and methods of use thereof |
| 01/16/2003 | WO2001091739A3 Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
| 01/16/2003 | WO2001090156A3 Card domain containing polypeptides, encoding nucleic acids, and methods of use |
| 01/16/2003 | WO2001089456A9 Hybrid lt-a/ct-b holotoxin for use as an adjuvant |
| 01/16/2003 | WO2001087937A3 G-protein coupled receptors |
| 01/16/2003 | WO2001070174A8 Vegf-modulated genes and methods employing them |
| 01/16/2003 | WO2001064944A9 MODULATION OF PLEIOTROPHIN SIGNALING BY RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE β/$g(z) |
| 01/16/2003 | WO2001059093A9 Full-length infectious cdna clones of tick borne flavivirus |
| 01/16/2003 | WO2001058954A9 Trade molecules and uses related thereto |
| 01/16/2003 | WO2001051049A9 O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders |
| 01/16/2003 | US20030013844 Multimerization of HIV-1 Vif protein as a therapeutic target |
| 01/16/2003 | US20030013191 Transgenic cells for use in human therapeutics and diagnostics |
| 01/16/2003 | US20030013190 Altered strain of the modified vaccinia virus ankara (mva) |
| 01/16/2003 | US20030013144 Detection of modulator of cancer activity; obtain sample containing biopolymers, incubate with modulator, monitor cellular response |
| 01/16/2003 | US20030013132 Non-invasive localization of a light-emitting conjugate in a mammal |
| 01/16/2003 | US20030013122 Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| 01/16/2003 | US20030013081 Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
| 01/16/2003 | US20030013077 Binding to monoclonal antibodies; detection of Kaposi's sarcoma |
| 01/16/2003 | US20030013076 Viral vector for use as tool in genetic engineering and human therapeutics |
| 01/16/2003 | US20030012817 Modified amino acids and derivatives can form non-covalent mixtures with active biological agents and in an alternate embodiment can releasably carry active agents. Modified amino acids can also form drug containing microspheres. |
| 01/16/2003 | US20030012794 Kits comprising heat shock protein-antigenic molecule complexes |
| 01/16/2003 | US20030012791 Use of cytokines and mitogens to inhibit graft versus host disease |
| 01/16/2003 | US20030012790 Especially bispecific molecules comprising an IFN- gamma inhibitor and a further specificity to a target involved in the initiation or development of IBD, including ulcerative colitis and Crohn's disease. |
| 01/16/2003 | US20030012789 Conjugate of an antigen and a FcRn binding partner, wherein the antigen is characteristic of a tumor, and a pharmaceutically acceptable carrier |
| 01/16/2003 | US20030012787 Especially for ulcerative colitis and Crohn's disease. |
| 01/16/2003 | US20030012784 Methods for treatment of inflammatory diseases |
| 01/16/2003 | US20030012783 Interfere with the binding of a tumor necrosis factor receptor with its ligand; inhibiting the proliferation of tumor cells |
| 01/16/2003 | US20030012782 Method and composition for altering a T cell mediated pathology |
| 01/16/2003 | US20030012781 Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
| 01/16/2003 | US20030012779 Reducing the residual solvent content to a level effective to protect said preparation of monoclonal immunoglobulins from said radiation; optionally adding a stabilizer; and irradiating with a suitable radiation |
| 01/16/2003 | US20030012767 Tissue-specific taanscriptional regulatory sequence operably linked to the coding region of a gene that is essential for replication of said vector. |
| 01/16/2003 | CA2785699A1 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 01/16/2003 | CA2467006A1 Nucleic acids encoding recombinant 56 and 82 kda antigens from gametocytes of eimeria maxima and their uses |
| 01/16/2003 | CA2462951A1 Isolation and purification of plasmodium falciparum merozoite protein-142 |
| 01/16/2003 | CA2453173A1 Mycobacterial antigens expressed during latency |
| 01/16/2003 | CA2453100A1 Novel human hepatoma lines, methods for obtaining same and uses thereof |
| 01/16/2003 | CA2453098A1 Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
| 01/16/2003 | CA2453075A1 Drug metabolizing enzymes |
| 01/16/2003 | CA2453062A1 Group b streptococcus bvh-a5 antigens and corresponding dna fragments |
| 01/16/2003 | CA2453042A1 Immunological binding molecules inhibiting the syncytial fusion of trophoblast cells |
| 01/16/2003 | CA2452695A1 Novel surface exposed immunoglobulin d-binding protein from moraxella catarrhalis |
| 01/16/2003 | CA2452666A1 Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle |
| 01/16/2003 | CA2452628A1 Methylation of histone h4 at arginine 3 |
| 01/16/2003 | CA2452580A1 Mycoplasma bovis vaccine and methods of reducing pneumonia in animals |
| 01/16/2003 | CA2452501A1 Secreted proteins |
| 01/16/2003 | CA2452119A1 Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof |
| 01/16/2003 | CA2451741A1 Peyers's patch and/or m-celle targeting ligands |
| 01/16/2003 | CA2451479A1 Methods for inducing an immune response with an elevated th1/th2 ratio, by intracellular induction of nfkappab |
| 01/16/2003 | CA2451374A1 Aggrecanase molecules |
| 01/16/2003 | CA2451055A1 Xenogenic oligoor/and polyribonucleotides as agents for the treatment of malignant tumours |
| 01/16/2003 | CA2450236A1 Phage displayed pdz domain ligands |
| 01/16/2003 | CA2449828A1 Detection and therapy of vulnerable plaque with photodynamic compounds |
| 01/15/2003 | EP1275965A1 Method for identifying substances which modulate interleukin 4 (IL-4) signaling |
| 01/15/2003 | EP1275726A2 A method for producing influenza hemagglutinin multivalent vaccines |
| 01/15/2003 | EP1275720A2 Histidyl-trna synthetase of staphylococcus aureus |
| 01/15/2003 | EP1275716A2 Modified DNA molecule, recombinant containing the same thing, and uses thereof |
| 01/15/2003 | EP1275638A1 Combination therapy for the treatment of immunological disorders |
| 01/15/2003 | EP1275400A1 Therapeutic composition of non MHC-restricted T-cells/NK-cells and MHC-restricted cells for the treatment of tumors |
| 01/15/2003 | EP1275380A1 Use of microparticles with adsorbed antigen to stimulate immune responses |
| 01/15/2003 | EP1274862A1 Control of a gene induced by oxidized lipids in human artery wall cells |
| 01/15/2003 | EP1274861A1 Compositions and methods for identifying and targeting cancer cells |
| 01/15/2003 | EP1274853A1 Materials and methods relating to immune responses to fusion proteins |
| 01/15/2003 | EP1274852A2 Targeted vaccine delivery systems |
| 01/15/2003 | EP1274851A1 A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus orf2, and an antigenic polypeptide |
| 01/15/2003 | EP1274844A2 G-protein coupled receptors and nucleic acids encoding same |
| 01/15/2003 | EP1274841A2 Regulation of human cyslt2-like gpcr protein |
| 01/15/2003 | EP1274840A2 Ligand for herpes simplex virus entry mediator and methods of use |
| 01/15/2003 | EP1274833A2 A method to prevent graft rejection using tgf-beta to induce t suppressor cells |
| 01/15/2003 | EP1274733A1 Surface-bound antigen binding portions of antibodies that bind to ctla-4 and cd28 and uses therefor |
| 01/15/2003 | EP1274732A1 Secretory tyrosine phosphatases from mycobacteria |
| 01/15/2003 | EP1274725A2 Neutralizing immunogenic hev polypeptides |
| 01/15/2003 | EP1274720A1 Albumin fusion proteins |
| 01/15/2003 | EP1274719A2 Albumin fusion proteins |
| 01/15/2003 | EP1274455A1 Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions |
| 01/15/2003 | EP1274454A2 Methods and compositions for eliciting an immune response |
| 01/15/2003 | EP1274453A2 Recombinant intracellular pathogen vaccines and methods for use |
| 01/15/2003 | EP1274450A2 Cytokine uses; compositions; methods |
| 01/15/2003 | EP1274305A2 Aids ancestral viruses and vaccines |
| 01/15/2003 | EP1107779B1 Medicaments for manipulating t-cell immune response |
| 01/15/2003 | EP0815235B1 Vaccines for plague |
| 01/15/2003 | EP0749981B1 Monoclonal antibody specific for pd-ecgf / thymidine phosphorylase |
| 01/15/2003 | EP0671927B1 Human neutralizing monoclonal antibodies to respiratory syncytial virus |
| 01/15/2003 | CN1391610A BASB118 polypeptide and polynucleotide from moraxella catarrhalis |
| 01/15/2003 | CN1391609A Use of replication-deficient adenoviral vector to boost CD8+T cell immune response to antigen |
| 01/15/2003 | CN1391608A Cloning, expression and characterisation of gene expressed in tumour cells and involved in regulation of immune response |
| 01/15/2003 | CN1391579A HEV antigenic peptide and its method |
| 01/15/2003 | CN1391483A Composition of octoxinol and polyvinyl chloride sorbitanate as accessory and uses in vaccins |
| 01/15/2003 | CN1391482A Therapy |
| 01/15/2003 | CN1391481A 疫苗 Vaccine |
| 01/15/2003 | CN1391480A Compositions and methods for treatment of allergic disorders |
| 01/15/2003 | CN1391479A Medicament for inducing tolerance |
| 01/15/2003 | CN1391463A Intranasal influenza virus vaccine |
| 01/15/2003 | CN1390604A Method for large-scale continuous production of virus vaccine |
| 01/15/2003 | CN1098652C Prepn. of immunity food by immunity method, and method thereof |
| 01/14/2003 | US6506891 Cell surface molecule-induced macrophage activation |
| 01/14/2003 | US6506883 Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use |
| 01/14/2003 | US6506881 Specific for human milk fat globule; complementarity determining region derived from variable domains of mouse monoclonal antibody |
| 01/14/2003 | US6506875 Diagnostic epitopes |